Aaron Koenig, MD, the chief medical officer of Delix Therapeutics, shares what try to be looking out for associated to the novel neuroplastogen, DLX-001, at the moment below research for sufferers with MDD.
Researchers have accomplished the section 1 research in wholesome volunteers. Now, they’ll start additional analysis to substantiate this potential remedy’s effectiveness.
- Delix has began dosing in a single-site, section 1b translational research. Outcomes might be shared mid 2025.
- Additionally round mid 2025, researchers will begin the section 2 randomized managed trial in sufferers with MDD at a number of websites.
See extra on DLX-001 from Dr Koenig right here.
Dr Koenig at the moment serves as chief medical officer for Delix Therapeutics, is a diplomate of the American Board of Psychiatry and Neurology, and retains lively board certification in grownup and geriatric psychiatry.
